US20020028260A1 - Plant proanthocyanidin extracts - Google Patents
Plant proanthocyanidin extracts Download PDFInfo
- Publication number
- US20020028260A1 US20020028260A1 US09/920,511 US92051101A US2002028260A1 US 20020028260 A1 US20020028260 A1 US 20020028260A1 US 92051101 A US92051101 A US 92051101A US 2002028260 A1 US2002028260 A1 US 2002028260A1
- Authority
- US
- United States
- Prior art keywords
- units
- type
- proanthocyanidin
- coli
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 title claims abstract description 153
- 239000000284 extract Substances 0.000 title claims abstract description 139
- 229920001991 Proanthocyanidin Polymers 0.000 title claims abstract description 117
- 241000588724 Escherichia coli Species 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 80
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 68
- 230000004520 agglutination Effects 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 229920000642 polymer Polymers 0.000 claims abstract description 42
- 241000196324 Embryophyta Species 0.000 claims abstract description 39
- 208000015181 infectious disease Diseases 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 27
- 241000736767 Vaccinium Species 0.000 claims abstract description 20
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- -1 flavonol glucosides Chemical class 0.000 claims abstract description 18
- 235000012511 Vaccinium Nutrition 0.000 claims abstract description 14
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 120
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 235000012734 epicatechin Nutrition 0.000 claims description 39
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 38
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 38
- 229910001868 water Inorganic materials 0.000 claims description 35
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims description 34
- 235000013305 food Nutrition 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 241000894006 Bacteria Species 0.000 claims description 32
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 32
- 239000001301 oxygen Substances 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 17
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 17
- 235000004634 cranberry Nutrition 0.000 claims description 17
- 125000004387 flavanoid group Chemical group 0.000 claims description 17
- 239000000178 monomer Substances 0.000 claims description 17
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 10
- 235000000346 sugar Nutrition 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 241000219094 Vitaceae Species 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 9
- 150000008163 sugars Chemical class 0.000 claims description 9
- 241000772415 Neovison vison Species 0.000 claims description 8
- 241000700199 Cavia porcellus Species 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010048685 Oral infection Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 238000007818 agglutination assay Methods 0.000 claims description 4
- 238000011109 contamination Methods 0.000 claims description 4
- 201000003146 cystitis Diseases 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 241000208421 Ericaceae Species 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 244000144972 livestock Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims 3
- 239000012153 distilled water Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 206010023424 Kidney infection Diseases 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- 239000012134 supernatant fraction Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 235000015067 sauces Nutrition 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 229920002770 condensed tannin Polymers 0.000 abstract description 13
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 abstract description 9
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 abstract description 9
- 235000011957 flavonols Nutrition 0.000 abstract description 9
- 229920002414 procyanidin Polymers 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 230000004071 biological effect Effects 0.000 abstract description 3
- 229930182478 glucoside Natural products 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 229930002877 anthocyanin Natural products 0.000 description 12
- 235000010208 anthocyanin Nutrition 0.000 description 12
- 239000004410 anthocyanin Substances 0.000 description 12
- 150000004636 anthocyanins Chemical class 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 102100021870 ATP synthase subunit O, mitochondrial Human genes 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 10
- 235000005487 catechin Nutrition 0.000 description 10
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 8
- 229950001002 cianidanol Drugs 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical group C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 6
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 6
- 244000291414 Vaccinium oxycoccus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 235000021019 cranberries Nutrition 0.000 description 5
- 235000020237 cranberry extract Nutrition 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 150000007946 flavonol Chemical class 0.000 description 5
- 229910004373 HOAc Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 235000011987 flavanols Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004403 catechin group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical group [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- SJWFXCIHNDVPSH-UHFFFAOYSA-N octan-2-ol Chemical compound CCCCCCC(C)O SJWFXCIHNDVPSH-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000021309 simple sugar Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940100611 topical cream Drugs 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 150000005835 flavan-3,4-diols Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229930185824 macrocarpon Natural products 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to plant extracts having therapeutic and other uses; more particularly to extracts of Vitaceae and Ericaceae families.
- proanthocyanidins are polyphenolic molecules found in fruits, berries and other plant material. These molecules belong to the flavanoid family of compounds.
- the flavanoid polyphenolics include the catechins, anthocyanins and proanthocyanidins.
- Proanthocyanidins are also known in the industry as leucoanthocyanins, leucodelphinins, leucocyanins, anthocyanogens, epicatechin-catechin polymers or procyanidins.
- the invention includes compounds isolated from plant materials, particularly plants of the genus Vaccinium, which have biological activity measurable as inhibition of adhesion of bacteria to surfaces, and an extract of such plant materials which is significantly enriched for anti-adhesion activity.
- Other preferred plants include members of the Vitaceae family, particularly of the Vitus genus.
- the specific compounds include procyanidins (also known as “condensed tannins”), leukocyanin and leucodelphinin, and flavonol glucosides including myricetin-3-pyranoside.
- An exemplary, preferred procyanidin compound is a substituted epicatechin-catechin dimer.
- the present invention is further directed to proanthocyanidin extracts.
- a peak of 95 ppm on a 13 C NMR spectrum is found in these proanthocyanidin compositions, which is an inherent characteristic of the Howell compounds illustrating an A-type linkage.
- These extracts may be free of tannins, lipids, carbohydrates, simple sugars, protein and amino acids and organic acids as well as being substantially free of anthocyanins.
- these proanthocyanidin extracts are capable of inhibiting agglutination reactions of P-type E. coli.
- the proanthocyanidin extracts contain at least one A-type interflavanoid bond.
- the invention also includes a method of making an extract having the properties outlined in the preceding paragraphs and a method of inhibiting the adhesion of bacteria to surfaces using the extract.
- the extract having the properties previously described for example, the peak at 95 ppm on the 13 C NMR spectrum, can be used to inhibit P-type E. coli, but are incapable of inhibiting agglutination of type 1 E. coli.
- the proanthocyanidin composition of the invention can be administered as a pharmaceutical composition.
- the pharmaceutical composition includes the proanthocyanidin extract and a pharmaceutically acceptable carrier such as lactose, cellulose, or an equivalent, or can be contained within a pharmaceutical dosage such as a capsule or tablet.
- Another aspect of the invention relates to methods of preventing or treating urogenital infections in a mammal by administering a proanthocyanidin composition including the proanthocyanidin extract, a proanthocyanidin compound, a proanthocyanidin polymer or a mixture thereof to the mammal in an amount and for a time sufficient to prevent, reduce or eliminate the symptoms associated with such infections and thereby lead to an amelioration or curing of the infection.
- the mammal undergoing treatment is human, but the method is also applicable to animals, such as mink.
- the proanthocyanidin composition of the invention can be used to reduce the pathogenesis of P-type E. coli found in the digestive tracts of animals such as mink and other mammals.
- a further aspect of the invention relates to methods of reducing the incidence of infection after surgery, treating topical wounds and acne, and preventing or eliminating oral infections using the proanthocyanidin composition of the invention.
- the invention further embraces compositions produced by first extracting non-active compounds from plant materials with, for example, a solvent, leaving a pulp or residue enriched for the anti-adhesion active fraction.
- This pulp or residue may be further processed by acid solubilization followed by selected steps as described in the preceding paragraphs to further enrich for the active fraction. (See, e.g., FIG. 1).
- the extract's anti-adhesion property is useful in a number of areas, for example, in the cleaning of industrial fermentation equipment, medical and dental instruments, medical dressings, laboratory culture jars, and the like.
- the extract may further have usefulness to inhibit the adhesion of bacteria to surgical implants, to tooth surfaces and oral cell types found in the mouth, and to cells in the urinary tract of humans and/or animals.
- a method of inhibiting the adhesion of bacteria includes the steps of providing the described extract, applying the extract in a suitable medium to a surface having bacteria such as E. coli adhered thereto and disengaging the bacteria from the surface.
- the method is useful to inhibit the adhesion of bacteria to such surfaces as teeth, other bacteria adhered to teeth, to human oral epithelial and urinary tract cells; and to clean dental implants, bacterial fermentation vats, and the like.
- FIG. 1 is a flow chart of an alternate method of extract preparation.
- FIG. 2 is a summary of the 13 C NMR data.
- FIGS. 3 A- 3 D are charts depicting an 13 C NMR spectrum of the active material isolated as per FIG. 1.
- FIGS. 4 A- 4 C depict HPLC chromatograms of the products from the selected steps of the process outlined in FIG. 1.
- FIG. 5 is a flow chart of an alternate method of extract preparation.
- FIGS. 6 A- 6 G depict HPLC chromatograms of the products from the selected steps of the process outlined in FIG. 5.
- FIG. 7 is a chart depicting a 13 C NMR spectrum of the active material isolated as per FIG. 5.
- FIG. 8 is a chart depicting an 1 H-NMR spectrum of the active material isolated as per FIG. 5.
- FIGS. 9A & 9B are charts depicting mass spectrograms of the active material isolated as per FIG. 5.
- the invention includes an extract of a plant, preferably a species of the genus Vaccinium, which is highly enriched for an active fraction having activity to inhibit the adherence of certain bacterial species to various substrates.
- Other plants that have demonstrated the ability to inhibit the adherence of certain bacterial species suitable for use in the present invention include members of the Vitaceae family.
- the Vaccinium extract is the preferred embodiment. It may be in powdered form or dissolved in a suitable solvent. The powdered form generally is a reddish powder with other properties as described herein.
- the extract will be referred to as the “enriched extract,” and, when reference is made to an extract made from a particular species such as cranberries, as the “cranberry extract.” Additionally, a peak of 95 ppm on a 13 C NMR spectrum is found in the extract.
- the extract is produced from a powder mass and is then separated using a methanol mix. Any undissolved solids are removed (such as by filtration or centrifugation). The extract polarity is increased by evaporation of organic solvents or by the addition of a polar solvent.
- the solution is applied to a C18 lipophilic column (Waters SepPak) which has been preconditioned with methanol (“MeOH”) followed by deionized water. After the cranberry-derived solution has been loaded into the column, the C18 column is washed with 2 to 3 column volumes of water, and eluted in stepwise fashion with MeOH:H 2 O mixtures of varying proportions. The solvent is then removed from the extract.
- methanol methanol
- the sample is separated using a water extract.
- the precipitate is removed and the aqueous layer is placed into a C18 lipophilic column.
- the void is removed, placed into a rotary evaporator, re-suspended and re-separated.
- the column is then washed with water to remove the sugars.
- Methanol is added into the column to take out the remaining compounds, which are then placed in a rotary evaporator and reduced before being re-suspended in water.
- the extract is then subjected to a 50:50 chloroform/ethyl acetate mixture before being separated into organic and aqueous layers. Both layers are then separately placed in the rotary evaporator.
- a similar embodiment includes separating the extract using methanol and then following the same procedure outlined in the preceding embodiment.
- Another embodiment of the invention involves taking the extract of a 10% cranberry solution and applying it to a C18 lipophilic column.
- the lipophilic column is then washed with water to remove the sugars.
- Methanol is introduced to removed the active compounds from the lipophilic column.
- the methanol extract is then centrifuged and/or filtered and the supernatant is placed in a rotary evaporator to dry.
- the pellet is then resuspended in water and then separated using a 50/50 mixture of chloroform (“CHCl 3 ”) with ethyl acetate (“EtOAc”).
- the organic layer is removed and the aqueous layer is subjected to the rotary evaporator and resuspension in water.
- the extract is then placed in a cation column to remove the cyanins, where the extract is again placed in a rotary evaporator before being placed in a gel permeation column to determine the molecular weight.
- Yet another embodiment uses a method similar to that previously identified. The differences include using the 50:50 chloroform and ethyl acetate separation process at the beginning, before the extract is run through the C18 lipophilic column. The rest of the procedure follows the steps in the aforementioned paragraph.
- the berries are separated using a solvent selected from the group including: methanol; ethanol; acetone; water; ethyl acetate; PET ether; diethyl ether; n-butanol; methanol: acetic acid (“HOAc”): water; (“MAW”), (10:1:10); ethyl acetate: acetic acid: EtAc: HOAc: EtOH, (10:1:10); EtAc: HOAc: EtOH, (10:1:5); Ethyl EtAc: HOAc: EtOH, (5:1:10); CHCl 3 : EtAc, (50:50); chloroform: ethyl acetate; CHCl 3 ; acetonitrile ; butanol: acenic acid: water, “BAW”, (6:1:2); methanol: acetone, (4:1); 5% NH 3 in ethanol; 5% NH 3 in
- the precipitate that is separated from the solvent list discussed above is extracted with methanol and separated.
- the solvent from the first extraction is placed into a rotary evaporator before being re-suspended in water.
- the extract is then placed into a 50/50 mixture of chloroform and ethyl acetate.
- the aqueous layer that corresponds with the solvent from the first extract is similarly placed in a rotary evaporator to remove the organic solvents.
- the aqueous layer that corresponds with the solvent from the first extract is then placed in a C18 lipophilic column. The column is washed with sufficient water before methanol is used to remove the fraction from the column.
- the fraction containing the extract is then placed in a rotary evaporator before resuspension in water.
- the extract is then placed in a cation column where it is washed with hydrochloric acid and methanol. The solvent is then removed from the extract.
- Yet another embodiment of the present invention includes taking the sample and combining it with one of the solvents mentioned previously to separate the desired extract from the sample.
- the organic layer is placed in a rotary evaporator and the precipitate and water-soluble extract are separated.
- the aqueous extract is combined with another solvent from the aforementioned list and again separated into organic and aqueous layers.
- the organic layer is again evaporated and is subjected to the same treatment as the aqueous layer.
- the extract can be separated continuously using solvents from the aforementioned list.
- the concentration of the extract is enriched by at least about 500- to 1500-fold for anti-adhesion activity, as compared with juices which are 100% derived from the plant material.
- the extract is enriched to a similar degree in the concentration of flavonoid and other polyphenol compounds detected by spectroscopic methods.
- the extract is very low in acid and in simple sugars, with a benzoic acid content typically less than about 0.01 milligrams per gram dry powder and essentially undetectable amounts of free monomer or dimer sugars.
- the preferred extract is prepared from cranberries ( V macrocarpon and variants such as grapes).
- V myrtilis bilberry
- V oxycoccus European cranberry
- V corymbosum blueberries
- a preferred method of producing the extract includes the steps of preparing a starting extract from plants or plant parts of species selected from the genus Vaccinium (wherein the starting extract includes both charged and polar compounds in the active fraction), concentrating the extract to a smaller volume and enriching the extract for the active fraction, and testing for polyphenol and flavonoid compounds generally.
- the method includes the further steps of removing most of the free monomer and dimer sugars from the extract, removing most of the benzoic acid from the extract, and removing anthocyanins. Steps following the preparation of a starting extract are not necessarily performed in the order listed. Techniques are described for accomplishing each of the indicated steps by chromatography or by precipitation and phase extraction steps. Additionally, in one embodiment, the method includes a step of mannose affinity chromatography which selects for compounds that can compete for binding to a mannose-affinic substrate.
- the proanthocyanidin extract can be further fractionated using HPLC or other techniques to identify and characterize specific proanthocyanidin compounds that have anti-adherence activity against P-type E. coli or other microorganisms.
- Such compounds include 1) proanthocyanidin compounds having an average of at least two to thirty epicatechin flavanoid units, each linked to the next by a B-type interflavanoid bond, and 2) proanthocyanidin compounds having an average of one or more epicatechin flavanoid units, i.e., four to seven epicatechin units, each linked to the next by at least one A-type interflavanoid bond.
- One procedure for preparing a cranberry extract having anti-adhesion activity which further includes the step of substantially purifying an active compound from the extract, begins with an alkaline pH extraction of the plant material in which the “active” compounds are precipitated.
- OSCP solution aqueous solution of OCEAN SPRAYTM cranberry powder
- the method is as follows. A sufficient amount of a strong base (e.g., NaOH) is added to the OSCP solution to bring it to a pH, generally about pH 9 or above, sufficient to ionize phenol groups of polyphenols to phenoxide groups. When the process is applied to the OSCP solution, the solution turns green upon reaching the necessary pH.
- a strong base e.g., NaOH
- the precipitate is allowed to settle, is collected on filter paper, and then is washed with a small volume (about 1 ⁇ 5 to 1 ⁇ 3 liter in the example) of “basic” methanol.
- the “basic” methanol is alkalinized with about 1-2 ml of 10N NaOH per liter.
- the washed solids are air dried, and the resulting light green powder, which contains increased levels of the active fraction as revealed by testing in the RBC agglutination assay described herein, is stable for many months at room temperature. Also, most of the sugars are removed in this step. Generally, between about 70 and about 80 grams of green powder are recovered per liter of 20% OSCP.
- a sufficient amount of the green powder is dissolved in 200 ml of water to make a strong or nearly saturated solution (generally 30-40 grams for the 20% OSCP process).
- the aqueous solution is then acidified to convert the phenoxide ions back to phenol groups, in the present case, by adding sufficient concentrated acid (about 13-16 ml of 12 M HCl) to bring it to between about pH 3 and about pH 4.
- sufficient concentrated acid about 13-16 ml of 12 M HCl
- C18 lipophilic column e.g., Waters SepPak
- methanol methanol
- deionized water a C18 lipophilic column
- the C18 column is washed with 2-3 column volumes of water, and eluted in stepwise fashion with MeOH:H 2 O mixtures of varying proportion.
- a 35 ml C18 column having about 200 ml of the acidified cranberry-derived solution loaded thereon can be eluted in a first elution step with 100 ml (2-3 column volumes) of a mixture of 10:90 MeOH/H 2 O (vol./vol.), a next elution step with 100 ml of 20:80 MeOH/H 2 O, a subsequent elution step with 30:70 MeOH/H 2 O, and a final elution step with 40:60 MeOH/H 2 O.
- Other water-miscible alcohols could be substituted for methanol, with appropriate adjustment to the alcohol:water proportions to achieve the desired separation.
- the eluate of the 30:70 wash is highly enriched for anti-adhesion activity, and includes the procyanidin compound.
- the 30:70 wash step eluant is brought to 50% MeOH, either by evaporation and redissolution or by adding MeOH.
- MeOH 50% MeOH
- This solution is then applied to an LH-20 SEPHADEXTM column (available from Sigma Chemical Co., of St. Louis, Mo.) which has been pre-conditioned with 50:50 MeOH/H 2 O.
- the column volume should generally be about ⁇ fraction (1/10) ⁇ to about 1 ⁇ 2 of the starting volume of the acidified solution.
- LH-20 column After loading the 50:50 MeOH-adjusted solution of the eluate on the LH-20 column, the column is washed with 50:50 MeOH/H 2 O. The LH-20 column is then eluted with about 2-3 column volumes of 70% acetone in water (vol./vol.); the eluate is evaporated to dryness and redissolved in water. The LH-20 column achieves selective separation of catechins, procyanidin polymers, and other polyphenols absorbing at 280 nm from other polyphenolic compounds. To achieve a similar separation, a phenyl-SEPHAROSETM column or an LH-60 column (Sigma Chemical Co.) could be substituted for the LH-20. Both LH-20 and LH-60 SEPHADEXTM include hydroxypropyl groups pendant via ether linkages from SEPHADEXTM beads, making the SEPHADEXTM material more lipophilic.
- the LH-20 eluate redissolved in water (in neutral form, or preferably acidified) is then applied to another C18 lipophilic column, and subjected to the same stepwise elution protocol.
- the eluate from the 30% MeOH eluant contains substantially a single compound absorbing at 280 nm, eluting at 18-19 minutes in the analytical HPLC procedure outlined previously herein (FIG. 6D).
- FOG. 6D analytical HPLC procedure outlined previously herein
- Generally, between about 0.03 and about 0.10 grams of the purified compound are recovered from 1 liter of the 20% OSCP, that is, a recovery of about 0.01% to about 0.05%. This recovery of a single active compound is at least 20-fold the recovery of mixed active compounds achieved by the methods described previously herein.
- FIGS. 6 B- 6 D depict analytical HPLC chromatograms of products from various steps in the described process.
- FIG. 6A is an HPLC chromatogram showing the retention time of two marker standards, catechin (peak 1400) and epicatechin (peak 1402), in the same HPLC protocol as FIGS. 6 B-D.
- FIG. 6B is a chromatogram of the product of the eluate after the wash precipitate and air dry, analyzed for compounds absorbing at 280 nm and for compounds absorbing at 360 nm.
- FIG. 6C shows a chromatogram of the product after the 70:30 wash of acetone:water, also analyzed for compounds absorbing at 280 nm and at 360 nm.
- FIG. 6D shows a chromatogram of the product of the 20:80 wash methanol:water, from which it is evident that essentially no 360 nm-absorbing compounds remain.
- the eluate of the step of the 20:80 wash has been subjected to 13 C and 1 H nuclear magnetic resonance (“NMR”) analysis, mass spectrometry, and infrared absorbance analysis.
- NMR nuclear magnetic resonance
- the 13 C NMR analysis shows an A-type interflavanoid linkage which results when the flavanoid units are joined by two bonds, with one bond occurring between C4 of one unit and C8 of a second unit, while another bond occurs between C2 of one unit and the oxygen attached to C7 of a second unit. Thus, an additional six-membered ring is formed.
- One of the embodiments of the present invention provides methods of preventing or treating urogenital infections in a mammal by administering a composition including the proanthocyanidin extract or proanthocyanidin compounds of the invention to the mammal in an amount and for a time sufficient to prevent, reduce or eliminate the symptoms associated with such infection and thereby lead to amelioration or curing of the infection.
- the composition can also be a pharmaceutical composition or food composition and can be administered for a time an in an amount sufficient to reduce or eliminate the bacteria associated with urogenital infections and thereby ameliorate or cure the infection.
- the proanthocyanidins compositions of the invention can be used directly as food additives or mixed with a consumable carrier to be used as a food additive or food composition.
- One food additive of the invention includes a proanthocyanidin extract of a Vaccinium species and a consumable carrier, wherein the extract is capable of inhibiting agglutination of P-type E. coli.
- Another food additive of the invention includes one or more proanthocyanidin compounds consisting of an average from at least two to thirty epicatechin flavanoid units, wherein each unit is linked to the next by B-type interflavanoid bonds or proanthocyanidin oligomers as well as being linked to at least one A-type interflavanoid linkage.
- the proanthocyanidins can be mixed in with a consumable food product.
- This consumable food product can be used as a food composition for livestock or animal feed.
- the food compositions can be used in a therapeutic fashion to prevent or treat urogenital infections.
- the food compositions can also be used for beverages, grain products, fruit products and the like.
- the present invention provides a method of inhibiting adherence of P-type E. coli to a surface which includes placing the bacteria in contact with at least one proanthocyanidin composition prior to (or concurrently with) allowing the bacteria to contact the surface.
- the surface may be any substance or material, synthetic or biological, where it is desired to prevent bacterial contamination, accumulation or infection.
- the surface can also be or constitute a biofilm.
- the surface is a cellular surface such as a uroepithelial cell surface, cells exposed in a wound or on the skin, a prosthetic device surface, an implant surface or a biofilm.
- the proanthocyanidin compositions of the invention can also be used for reducing or treating infection after surgery, treating topical wounds or acne, or preventing or eliminating oral infection by administering a pharmaceutical composition of the invention to a site of infection or potential infection in a patient.
- the pharmaceutical composition is administered to the patient in accordance with the treatment being rendered.
- the composition can be applied to a surgical incision or other opening as a liquid, topical cream or by any other suitable delivery means.
- the pharmaceutical composition can be a topical cream, salve, dermal antiseptic, dressing (e.g., gauze, tape, etc.) or spray.
- Another aspect of the present invention is directed to a method of detecting P-type reactive bacteria in a body fluid sample.
- This method includes contacting a body fluid sample with a P-type receptor specific assay reagent in an amount to allow for the binding of any P-type reactive bacteria which may be present in the sample to the reagent.
- the reagent includes a solid-phase substrate coated with one or more proanthocyanidin compositions of the invention.
- a determination of whether P-type reactive bacteria are present in the sample can be assessed by the degree of agglutination in said sample.
- the presence of P-type reactive bacteria, especially P-type E. coli can be determined if agglutination occurs in the sample.
- Another embodiment of the invention provides a test for use in detecting P-type bacteria in a body fluid sample.
- the test includes use of a P-type receptor-specific assay reagent which includes a solid-phase substrate coated with one or more proanthocyanidin compositions of the invention. Multiple serial dilutions of the sample or reagent can be used to conduct the assay.
- proanthocyanidin and proanthocyanidin polymers are believed to be potentiated or otherwise enhanced when combined with a substance selected from the group including Vaccinium-derived flavanols, especially galloyl-substituted tannins including gallocatechin, gallo-epicatechin, and pyranosides of these; Vaccinium-derived leukocyanins, and Vaccinium-derived flavonol pyranosides.
- a particularly preferred combination is the proanthocyanidin with the galloyl-substituted tannin, as the latter compounds are believed to inhibit enzymatic degradation of carbohydrate-substituted phenolic compounds.
- the Vaccinium flavanols appear to have little or no anti-adhesion activity. However, at least some Vaccinium-derived flavonol pyranosides do have anti-adhesion activity, although less than the proanthocyanidins.
- myricetin-3-pyranoside is one of the most prominent. This compound does have some anti-adhesion activity, but it's anti-adhesion activity is less than that of the proanthocyanidin(s).
- At least three modes of bacterial cell adherence to other cells and surfaces are known.
- One mode is mediated by type 1 pili on the surface of the bacteria and is characterized by sensitivity to free mannose.
- a second mode is mediated by P-type pili.
- the mechanisms of the third mode and other adherence modes are not well characterized.
- Guinea pig RBCs are believed to have receptors for the type 1 (mannose-sensitive) pili of E. coli, since the bacteria are capable of agglutinating guinea pig RBCs in the absence of mannose but not in its presence (see for example Aronsen, J. Infect. Dis. 139:329-332, 1979; Riegman, J. Bacter. 172: 1114-1120, 1990; Jann, Infect. Immun. 22:247-254, 1981).
- cells was isolated from an active bladder infection in a human subject. This strain, designated the #3B strain, appears to possess both type 1 and P-type pili (the latter are sometimes referred to in the research literature as “P-type fimbriae”).
- the anthocyanins used in the experiment shown in Table II were obtained from cranberries. The elution of the cation column with 1% HCl, after collection of the void volume and aqueous washes, is found to selectively recover much or all of the anthocyanin content of cranberry. The anthocyanin preparation did not contain significant amounts of other substances.
- the extract also reduced the adherence of Pseudomonas aeruginosa to bladder epithelial cells, although to a lesser degree than observed with E. coli. There was no apparent effect upon the adherence of several Lactobacillus strains to human bladder cells.
- E. coli did not adhere to polystyrene plastic in the presence of the extract. However, it should be noted that, in general, E. coli do not tend to greatly adhere to polystyrene.
- a cranberry extract is used as a feed supplement for male mink.
- male mink During the fall and early winter, male mink have a serious problem with bladder infections. This problem often occurs during the mating season and prevents the male mink from performing.
- a study was designed in which the mink were fed solid cranberry extract mixed in with their feed every morning. This study illustrated that the cranberry feed additive was helpful in reducing bladder infections in the male mink.
- the invention can also include compounds isolated from plant materials, particularly plants of the family Vitaceae, which have biological activity measurable as inhibition of adhesion of bacteria to surfaces, and an extract of such plant materials which is significantly enriched for anti-adhesion activity.
- plant materials particularly plants of the family Vitaceae, which have biological activity measurable as inhibition of adhesion of bacteria to surfaces
- an extract of such plant materials which is significantly enriched for anti-adhesion activity.
- FIGS. 6 B- 6 G depict analytical HPLC chromatograms of products from various steps in the process of FIG. 1.
- FIG. 6A is an HPLC chromatogram showing the retention time of two marker standards, catechin (peak 1400) and epicatechin (peak 1402), in the same HPLC protocol as FIGS. 6 B-D.
- FIG. 6B is a chromatogram of the product of washing and air drying the precipitate which was analyzed for compounds absorbing at 280 nm and for compounds absorbing at 360 nm.
- FIG. 6C shows a chromatogram of the product of the eluate washed in the column with a ratio of 70:30 of acetone: water, also analyzed for compounds absorbing at 280 nm and at 360 nm.
- FIG. 6D shows a chromatogram of the product of the wash of the eluate of methanol: water at a 20:80 ratio, from which it is evident that essentially no 360 nm-absorbing compounds remain.
- the eluate of this step has been subjected to 13 C and 1 H nuclear magnetic resonance analysis, mass spectrometry, and infrared absorbance analysis.
- FIG. 7 depicts a 13 C-NMR scan of product from the step of the 20:80 wash in d 6 -dimethylsulfoxide (“DMSO”).
- Peak 1600 is from the DMSO and methanol solvents.
- Peak 1604 represents a C4 carbon of an epicatechin ring system, while peak 1606 represents a C4 carbon of a catechin ring system.
- Peaks 1608 represent the C3 and C4 carbons of a B-ring of a flavanol (catechin) ring system.
- FIG. 8 depicts an 1 H-NMR scan of product from the aforementioned step, also in d 6 -DMSO.
- FIGS. 9A and 9B depict mass spectrograms of product from the aforementioned step, dissolved in 3- nitrobenzyl alcohol with DMSO.
- the product from the aforementioned step has many of the characteristics of a proanthocyanidin.
- the material in the region 1410 beneath the peak 1408 of the HPLC of FIG. 6C includes polymeric proanthocyanidins and that these polymeric proanthocyanidins are highly active as well polymeric proanthocyanidins.
- Proanthocyanidin oligomers or polymers useful for present anti-microbial methods include monomeric units of leucoanthocyandins.
- Leucoanthocyandins are generally monomeric flavonoids which include catechins, epicatechins, gallocatechins, galloepicatechins, flavonols, and flavan-3,4-diols leucocyanidins and anthocyanidins.
- the proanthocyanidin polymers have 2 to 30 flavonoid units.
- Certain other compounds present in the extract have been farther identified as having anti-adhesion activity, and in some cases these compounds have been partially purified. These include leukocyanidins/leukodelphinidins and flavonol pyranosides.
- Leukocyanidins/leukodelphinidins and flavonol pyranosides include a general structure of a catechin molecule (Merck Index # 1908); epicatechin differs from catechin in the orientation of the hydroxyl at position 3, and the hydrogen at position 2 of the phenol group.
- compounds having a ring system wherein the ring B may include oxygen at position 1, position 4, or both, and having a pyranoside as R 2 , have anti-adhesion activity.
- the ring B is further unsaturated except for the C ⁇ C bond shared with ring A.
- Evidence for the necessity of the unsaturation of ring B and the necessity of R 2 being a pyranoside is as follows.
- Leucoanthocyanins (exemplified as leucocyanin and leucodelphinin) are colorless compounds having the catechin or epicatechin ring structure with an unsaturated ring B and a pyranoside in the R 2 position.
- myricetin-3-pyranoside isolated from Vaccinium species does have anti-adhesion activity.
- one of the anti-adhesion assays described herein compares the ability of a substance to inhibit binding relative to mannose inhibition of such adhesion, and it is, therefore, believed that a carbohydrate moiety is involved in conferring anti-adhesion activity.
- the microbes whose adherence to cells is interfered with include bacteria, yeast and possibly viruses which bind to cell surfaces as a first step in infecting them.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds isolated from plant materials, particularly plants of the genus Vaccinium, which have biological activity measurable as inhibition with adhesion of bacterial cells to surfaces, and an extract of such plant materials which is significantly enriched for the anti-adhesion activity. The specific compounds include procyanidins (also known as “condensed tannins”), leukocyanin, leucodelphinin, flavonol glucosides including myricetin-3-pyranoside and proanthocyanidin extracts. These proanthocyanidin extracts are capable of inhibiting agglutination reactions of P-type E. Coli. The extracts containing proanthocyanidins contain at least one A-type interflavanoid bond. Methods of making an extract. Methods of preventing or treating urogenital infections in a mammal by administering a proanthocyanidin composition including the proanthocyanidin extract, a proanthocyanidin compound, a proanthocyanidin polymer or a mixture thereof, to a subjecct in an amount and for a time sufficient to prevent, reduce or eliminate symptoms associated with such infections.
Description
- This application is a divisional application of pending application U.S. Ser. No. 09/822,710, filed on Mar. 30, 2001, which is a divisional of application Ser. No. 09/391,308, now U.S. Pat. No. 6,210,681, filed Sep. 7, 1999, the contents of which is hereby incorporated by this reference.
- The invention relates to plant extracts having therapeutic and other uses; more particularly to extracts of Vitaceae and Ericaceae families.
- Analysis of the anti-bacterial adhesion fraction of cranberries and other species has been fruitful of late. For instance, the instant inventors, Edward B. Walker, Richard A. Mickelsen, Jr. and Jennifer N. Mickelsen have previously published their findings regarding the active anti-bacterial fraction in U.S. Pat. Nos. 5,525,341, 5,646,178, 5,650,432, and 5,474,774, the contents of all of which are incorporated herein by this reference in their entirety.
- Similarly, later work was evidently conducted at Rutgers University in an attempt to isolate an active fraction of cranberry and other species. See, e.g., Howell et al. “Inhibition of P-fimbriated Escherichia coli to Uroepithelial Cell Surfaces by Proanthocyanidin Extracts from Cranberries”,New England Journal of Medicine, 339(15):1085-6 (Oct. 8, 1998), and International Application No. PCT/US98/18267, published within a year of the priority date hereof on Mar. 18, 1999.
- As described in the foregoing patents and publications, proanthocyanidins are polyphenolic molecules found in fruits, berries and other plant material. These molecules belong to the flavanoid family of compounds. The flavanoid polyphenolics include the catechins, anthocyanins and proanthocyanidins. Proanthocyanidins are also known in the industry as leucoanthocyanins, leucodelphinins, leucocyanins, anthocyanogens, epicatechin-catechin polymers or procyanidins.
- The invention includes compounds isolated from plant materials, particularly plants of the genus Vaccinium, which have biological activity measurable as inhibition of adhesion of bacteria to surfaces, and an extract of such plant materials which is significantly enriched for anti-adhesion activity. Other preferred plants include members of the Vitaceae family, particularly of the Vitus genus. The specific compounds include procyanidins (also known as “condensed tannins”), leukocyanin and leucodelphinin, and flavonol glucosides including myricetin-3-pyranoside. An exemplary, preferred procyanidin compound is a substituted epicatechin-catechin dimer.
- The present invention is further directed to proanthocyanidin extracts. Specifically, a peak of 95 ppm on a13C NMR spectrum is found in these proanthocyanidin compositions, which is an inherent characteristic of the Howell compounds illustrating an A-type linkage. These extracts may be free of tannins, lipids, carbohydrates, simple sugars, protein and amino acids and organic acids as well as being substantially free of anthocyanins. Additionally, these proanthocyanidin extracts are capable of inhibiting agglutination reactions of P-type E. coli. As noted, the proanthocyanidin extracts contain at least one A-type interflavanoid bond.
- When the extract is analyzed by reverse-phase HPLC on a C18 lipophilic column, characteristic sets of elution peaks of compounds absorbing at 230 nm, 280 nm and 360 nm are observed. When subjected to further purification, one of the 280 nm-absorbing peaks is found to contain the exemplary procyanidin. The flavonol glucosides are purified from 360 nm-absorbing elution peaks. The pyranoside moiety in these compounds may be glucose, mannose, or a like sugar.
- The invention also includes a method of making an extract having the properties outlined in the preceding paragraphs and a method of inhibiting the adhesion of bacteria to surfaces using the extract.
- In another embodiment of the present invention, the extract having the properties previously described, for example, the peak at 95 ppm on the13C NMR spectrum, can be used to inhibit P-type E. coli, but are incapable of inhibiting agglutination of
type 1 E. coli. - In another embodiment, the proanthocyanidin composition of the invention can be administered as a pharmaceutical composition. The pharmaceutical composition includes the proanthocyanidin extract and a pharmaceutically acceptable carrier such as lactose, cellulose, or an equivalent, or can be contained within a pharmaceutical dosage such as a capsule or tablet.
- Another aspect of the invention relates to methods of preventing or treating urogenital infections in a mammal by administering a proanthocyanidin composition including the proanthocyanidin extract, a proanthocyanidin compound, a proanthocyanidin polymer or a mixture thereof to the mammal in an amount and for a time sufficient to prevent, reduce or eliminate the symptoms associated with such infections and thereby lead to an amelioration or curing of the infection. Preferably, the mammal undergoing treatment is human, but the method is also applicable to animals, such as mink.
- In another embodiment, the proanthocyanidin composition of the invention can be used to reduce the pathogenesis of P-typeE. coli found in the digestive tracts of animals such as mink and other mammals.
- A further aspect of the invention relates to methods of reducing the incidence of infection after surgery, treating topical wounds and acne, and preventing or eliminating oral infections using the proanthocyanidin composition of the invention.
- The invention further embraces compositions produced by first extracting non-active compounds from plant materials with, for example, a solvent, leaving a pulp or residue enriched for the anti-adhesion active fraction. This pulp or residue may be further processed by acid solubilization followed by selected steps as described in the preceding paragraphs to further enrich for the active fraction. (See, e.g., FIG. 1).
- The extract's anti-adhesion property is useful in a number of areas, for example, in the cleaning of industrial fermentation equipment, medical and dental instruments, medical dressings, laboratory culture jars, and the like. The extract may further have usefulness to inhibit the adhesion of bacteria to surgical implants, to tooth surfaces and oral cell types found in the mouth, and to cells in the urinary tract of humans and/or animals.
- A method of inhibiting the adhesion of bacteria includes the steps of providing the described extract, applying the extract in a suitable medium to a surface having bacteria such asE. coli adhered thereto and disengaging the bacteria from the surface. The method is useful to inhibit the adhesion of bacteria to such surfaces as teeth, other bacteria adhered to teeth, to human oral epithelial and urinary tract cells; and to clean dental implants, bacterial fermentation vats, and the like.
- FIG. 1 is a flow chart of an alternate method of extract preparation.
- FIG. 2 is a summary of the13C NMR data.
- FIGS.3A-3D are charts depicting an 13C NMR spectrum of the active material isolated as per FIG. 1.
- FIGS.4A-4C depict HPLC chromatograms of the products from the selected steps of the process outlined in FIG. 1.
- FIG. 5 is a flow chart of an alternate method of extract preparation.
- FIGS.6A-6G depict HPLC chromatograms of the products from the selected steps of the process outlined in FIG. 5.
- FIG. 7 is a chart depicting a13C NMR spectrum of the active material isolated as per FIG. 5.
- FIG. 8 is a chart depicting an1H-NMR spectrum of the active material isolated as per FIG. 5.
- FIGS. 9A & 9B are charts depicting mass spectrograms of the active material isolated as per FIG. 5.
- The invention includes an extract of a plant, preferably a species of the genus Vaccinium, which is highly enriched for an active fraction having activity to inhibit the adherence of certain bacterial species to various substrates. Other plants that have demonstrated the ability to inhibit the adherence of certain bacterial species suitable for use in the present invention include members of the Vitaceae family. The Vaccinium extract is the preferred embodiment. It may be in powdered form or dissolved in a suitable solvent. The powdered form generally is a reddish powder with other properties as described herein. For convenience and clarity, the extract will be referred to as the “enriched extract,” and, when reference is made to an extract made from a particular species such as cranberries, as the “cranberry extract.” Additionally, a peak of 95 ppm on a13C NMR spectrum is found in the extract.
- In one presently preferred embodiment of the invention, the extract is produced from a powder mass and is then separated using a methanol mix. Any undissolved solids are removed (such as by filtration or centrifugation). The extract polarity is increased by evaporation of organic solvents or by the addition of a polar solvent. Next, the solution is applied to a C18 lipophilic column (Waters SepPak) which has been preconditioned with methanol (“MeOH”) followed by deionized water. After the cranberry-derived solution has been loaded into the column, the C18 column is washed with 2 to 3 column volumes of water, and eluted in stepwise fashion with MeOH:H2O mixtures of varying proportions. The solvent is then removed from the extract.
- In yet another preferred embodiment, the sample is separated using a water extract. The precipitate is removed and the aqueous layer is placed into a C18 lipophilic column. The void is removed, placed into a rotary evaporator, re-suspended and re-separated. The column is then washed with water to remove the sugars. Methanol is added into the column to take out the remaining compounds, which are then placed in a rotary evaporator and reduced before being re-suspended in water. The extract is then subjected to a 50:50 chloroform/ethyl acetate mixture before being separated into organic and aqueous layers. Both layers are then separately placed in the rotary evaporator.
- A similar embodiment includes separating the extract using methanol and then following the same procedure outlined in the preceding embodiment.
- Another embodiment of the invention involves taking the extract of a 10% cranberry solution and applying it to a C18 lipophilic column. The lipophilic column is then washed with water to remove the sugars. Methanol is introduced to removed the active compounds from the lipophilic column. The methanol extract is then centrifuged and/or filtered and the supernatant is placed in a rotary evaporator to dry. The pellet is then resuspended in water and then separated using a 50/50 mixture of chloroform (“CHCl3”) with ethyl acetate (“EtOAc”). The organic layer is removed and the aqueous layer is subjected to the rotary evaporator and resuspension in water. The extract is then placed in a cation column to remove the cyanins, where the extract is again placed in a rotary evaporator before being placed in a gel permeation column to determine the molecular weight.
- Yet another embodiment uses a method similar to that previously identified. The differences include using the 50:50 chloroform and ethyl acetate separation process at the beginning, before the extract is run through the C18 lipophilic column. The rest of the procedure follows the steps in the aforementioned paragraph.
- In another embodiment of the present invention the berries are separated using a solvent selected from the group including: methanol; ethanol; acetone; water; ethyl acetate; PET ether; diethyl ether; n-butanol; methanol: acetic acid (“HOAc”): water; (“MAW”), (10:1:10); ethyl acetate: acetic acid: EtAc: HOAc: EtOH, (10:1:10); EtAc: HOAc: EtOH, (10:1:5); Ethyl EtAc: HOAc: EtOH, (5:1:10); CHCl3: EtAc, (50:50); chloroform: ethyl acetate; CHCl3; acetonitrile ; butanol: acenic acid: water, “BAW”, (6:1:2); methanol: acetone, (4:1); 5% NH3 in ethanol; 5% NH3 in acetone; 5% NH3 in acetonitrile; amyl alcohol (C5); hexanol (C6); heptanol (C7); 2-octanol (C8); n-decanol (C10); acetone: methanol (40:60); methanol with 2% HCl; CHCl3: EtAc (62:38); CHCl3: EtAc (59:41); hydrochloric acid; HCl 3N; hydrochloric acid; HCl 1N; methylene chloride; CH2Cl2; tetra hydrofuran (“THF”); hexane; potassium hydroxide (“KOH”) 6N; sodium hydroxide; 5% NaOH; sodium chloride; 0.85% NaCl; sodium hydroxide; NaOH IN; p-xylene; toluene; methanol: acetone (50:50).
- The precipitate that is separated from the solvent list discussed above is extracted with methanol and separated. The solvent from the first extraction is placed into a rotary evaporator before being re-suspended in water. The extract is then placed into a 50/50 mixture of chloroform and ethyl acetate. The aqueous layer that corresponds with the solvent from the first extract is similarly placed in a rotary evaporator to remove the organic solvents. The aqueous layer that corresponds with the solvent from the first extract is then placed in a C18 lipophilic column. The column is washed with sufficient water before methanol is used to remove the fraction from the column. The fraction containing the extract is then placed in a rotary evaporator before resuspension in water. The extract is then placed in a cation column where it is washed with hydrochloric acid and methanol. The solvent is then removed from the extract.
- Yet another embodiment of the present invention includes taking the sample and combining it with one of the solvents mentioned previously to separate the desired extract from the sample. The organic layer is placed in a rotary evaporator and the precipitate and water-soluble extract are separated. The aqueous extract is combined with another solvent from the aforementioned list and again separated into organic and aqueous layers. The organic layer is again evaporated and is subjected to the same treatment as the aqueous layer. The extract can be separated continuously using solvents from the aforementioned list.
- In a presently preferred embodiment, the concentration of the extract is enriched by at least about 500- to 1500-fold for anti-adhesion activity, as compared with juices which are 100% derived from the plant material. The extract is enriched to a similar degree in the concentration of flavonoid and other polyphenol compounds detected by spectroscopic methods.
- In a currently preferred embodiment, the extract is very low in acid and in simple sugars, with a benzoic acid content typically less than about 0.01 milligrams per gram dry powder and essentially undetectable amounts of free monomer or dimer sugars. The preferred extract is prepared from cranberries (V macrocarpon and variants such as grapes). However, other useful species are V myrtilis (bilberry), V oxycoccus (European cranberry), and V corymbosum (blueberries).
- A preferred method of producing the extract includes the steps of preparing a starting extract from plants or plant parts of species selected from the genus Vaccinium (wherein the starting extract includes both charged and polar compounds in the active fraction), concentrating the extract to a smaller volume and enriching the extract for the active fraction, and testing for polyphenol and flavonoid compounds generally. In a preferred embodiment, the method includes the further steps of removing most of the free monomer and dimer sugars from the extract, removing most of the benzoic acid from the extract, and removing anthocyanins. Steps following the preparation of a starting extract are not necessarily performed in the order listed. Techniques are described for accomplishing each of the indicated steps by chromatography or by precipitation and phase extraction steps. Additionally, in one embodiment, the method includes a step of mannose affinity chromatography which selects for compounds that can compete for binding to a mannose-affinic substrate.
- The proanthocyanidin extract can be further fractionated using HPLC or other techniques to identify and characterize specific proanthocyanidin compounds that have anti-adherence activity against P-typeE. coli or other microorganisms. Such compounds include 1) proanthocyanidin compounds having an average of at least two to thirty epicatechin flavanoid units, each linked to the next by a B-type interflavanoid bond, and 2) proanthocyanidin compounds having an average of one or more epicatechin flavanoid units, i.e., four to seven epicatechin units, each linked to the next by at least one A-type interflavanoid bond.
- One procedure for preparing a cranberry extract having anti-adhesion activity which further includes the step of substantially purifying an active compound from the extract, begins with an alkaline pH extraction of the plant material in which the “active” compounds are precipitated. As applied to an aqueous solution of OCEAN SPRAY™ cranberry powder (“OSCP solution”), the method is as follows. A sufficient amount of a strong base (e.g., NaOH) is added to the OSCP solution to bring it to a pH, generally about pH 9 or above, sufficient to ionize phenol groups of polyphenols to phenoxide groups. When the process is applied to the OSCP solution, the solution turns green upon reaching the necessary pH. For 1 liter of a saturated OSCP solution of cranberry powder (20% being generally as much as will dissolve into solution), about 70-80 ml of 10 N NaOH is used. The green, basic OSCP solution thus produced is then stirred with a sufficient amount of a simple alcohol to cause formation of a green precipitate. In the example starting with 1 liter of 20% OSCP, about 4 volumes (e.g., 4 liters) of methanol are used. In place of MeOH, other alcohols miscible with water, including ethanol, isopropanol, butanol, propanol, etc., could be used. The precipitate is allowed to settle, is collected on filter paper, and then is washed with a small volume (about ⅕ to ⅓ liter in the example) of “basic” methanol. The “basic” methanol is alkalinized with about 1-2 ml of 10N NaOH per liter. The washed solids are air dried, and the resulting light green powder, which contains increased levels of the active fraction as revealed by testing in the RBC agglutination assay described herein, is stable for many months at room temperature. Also, most of the sugars are removed in this step. Generally, between about 70 and about 80 grams of green powder are recovered per liter of 20% OSCP.
- Next, a sufficient amount of the green powder is dissolved in 200 ml of water to make a strong or nearly saturated solution (generally 30-40 grams for the 20% OSCP process). The aqueous solution is then acidified to convert the phenoxide ions back to phenol groups, in the present case, by adding sufficient concentrated acid (about 13-16 ml of 12 M HCl) to bring it to between about pH 3 and about
pH 4. In the case of extraction from OSCP, the solution turns to a wine-red color upon reaching the appropriate pH. Any undissolved solids are removed (e.g., by filtration or centrifugation), and the supernatant solution is applied to a C18 lipophilic column (e.g., Waters SepPak) which has been preconditioned with methanol followed by deionized water. After the cranberry-derived solution has been loaded onto the C18 column, the C18 column is washed with 2-3 column volumes of water, and eluted in stepwise fashion with MeOH:H2O mixtures of varying proportion. For example, and not by way of limitation, a 35 ml C18 column having about 200 ml of the acidified cranberry-derived solution loaded thereon, can be eluted in a first elution step with 100 ml (2-3 column volumes) of a mixture of 10:90 MeOH/H2O (vol./vol.), a next elution step with 100 ml of 20:80 MeOH/H2O, a subsequent elution step with 30:70 MeOH/H2O, and a final elution step with 40:60 MeOH/H2O. Other water-miscible alcohols could be substituted for methanol, with appropriate adjustment to the alcohol:water proportions to achieve the desired separation. Also, other organic solvents which are non-polar as compared to water, such as acetonitrile, could be substituted for the alcohol. Further, it is probable that other similar reverse-phase lipophilic columns, such as C2 and C8 columns, could be substituted for the C18 column. - The eluate of the 30:70 wash is highly enriched for anti-adhesion activity, and includes the procyanidin compound. To further purify the procyanidin, the 30:70 wash step eluant is brought to 50% MeOH, either by evaporation and redissolution or by adding MeOH. This solution is then applied to an LH-20 SEPHADEX™ column (available from Sigma Chemical Co., of St. Louis, Mo.) which has been pre-conditioned with 50:50 MeOH/H2O. The column volume should generally be about {fraction (1/10)} to about ½ of the starting volume of the acidified solution. After loading the 50:50 MeOH-adjusted solution of the eluate on the LH-20 column, the column is washed with 50:50 MeOH/H2O. The LH-20 column is then eluted with about 2-3 column volumes of 70% acetone in water (vol./vol.); the eluate is evaporated to dryness and redissolved in water. The LH-20 column achieves selective separation of catechins, procyanidin polymers, and other polyphenols absorbing at 280 nm from other polyphenolic compounds. To achieve a similar separation, a phenyl-SEPHAROSE™ column or an LH-60 column (Sigma Chemical Co.) could be substituted for the LH-20. Both LH-20 and LH-60 SEPHADEX™ include hydroxypropyl groups pendant via ether linkages from SEPHADEX™ beads, making the SEPHADEX™ material more lipophilic.
- The LH-20 eluate redissolved in water (in neutral form, or preferably acidified) is then applied to another C18 lipophilic column, and subjected to the same stepwise elution protocol. The eluate from the 30% MeOH eluant contains substantially a single compound absorbing at 280 nm, eluting at 18-19 minutes in the analytical HPLC procedure outlined previously herein (FIG. 6D). Generally, between about 0.03 and about 0.10 grams of the purified compound are recovered from 1 liter of the 20% OSCP, that is, a recovery of about 0.01% to about 0.05%. This recovery of a single active compound is at least 20-fold the recovery of mixed active compounds achieved by the methods described previously herein.
- FIGS.6B-6D depict analytical HPLC chromatograms of products from various steps in the described process. FIG. 6A is an HPLC chromatogram showing the retention time of two marker standards, catechin (peak 1400) and epicatechin (peak 1402), in the same HPLC protocol as FIGS. 6B-D. FIG. 6B is a chromatogram of the product of the eluate after the wash precipitate and air dry, analyzed for compounds absorbing at 280 nm and for compounds absorbing at 360 nm. FIG. 6C shows a chromatogram of the product after the 70:30 wash of acetone:water, also analyzed for compounds absorbing at 280 nm and at 360 nm. FIG. 6D shows a chromatogram of the product of the 20:80 wash methanol:water, from which it is evident that essentially no 360 nm-absorbing compounds remain.
- The eluate of the step of the 20:80 wash has been subjected to13C and 1H nuclear magnetic resonance (“NMR”) analysis, mass spectrometry, and infrared absorbance analysis.
- The13C NMR analysis shows an A-type interflavanoid linkage which results when the flavanoid units are joined by two bonds, with one bond occurring between C4 of one unit and C8 of a second unit, while another bond occurs between C2 of one unit and the oxygen attached to C7 of a second unit. Thus, an additional six-membered ring is formed.
- One of the embodiments of the present invention provides methods of preventing or treating urogenital infections in a mammal by administering a composition including the proanthocyanidin extract or proanthocyanidin compounds of the invention to the mammal in an amount and for a time sufficient to prevent, reduce or eliminate the symptoms associated with such infection and thereby lead to amelioration or curing of the infection. The composition can also be a pharmaceutical composition or food composition and can be administered for a time an in an amount sufficient to reduce or eliminate the bacteria associated with urogenital infections and thereby ameliorate or cure the infection.
- The proanthocyanidins compositions of the invention can be used directly as food additives or mixed with a consumable carrier to be used as a food additive or food composition. One food additive of the invention includes a proanthocyanidin extract of a Vaccinium species and a consumable carrier, wherein the extract is capable of inhibiting agglutination of P-typeE. coli. Another food additive of the invention includes one or more proanthocyanidin compounds consisting of an average from at least two to thirty epicatechin flavanoid units, wherein each unit is linked to the next by B-type interflavanoid bonds or proanthocyanidin oligomers as well as being linked to at least one A-type interflavanoid linkage.
- In another embodiment of the present invention, the proanthocyanidins can be mixed in with a consumable food product. This consumable food product can be used as a food composition for livestock or animal feed. The food compositions can be used in a therapeutic fashion to prevent or treat urogenital infections. The food compositions can also be used for beverages, grain products, fruit products and the like. In yet another embodiment, the present invention provides a method of inhibiting adherence of P-typeE. coli to a surface which includes placing the bacteria in contact with at least one proanthocyanidin composition prior to (or concurrently with) allowing the bacteria to contact the surface. The surface may be any substance or material, synthetic or biological, where it is desired to prevent bacterial contamination, accumulation or infection. In a preferred embodiment, the surface can also be or constitute a biofilm. In a preferred embodiment, the surface is a cellular surface such as a uroepithelial cell surface, cells exposed in a wound or on the skin, a prosthetic device surface, an implant surface or a biofilm.
- The proanthocyanidin compositions of the invention can also be used for reducing or treating infection after surgery, treating topical wounds or acne, or preventing or eliminating oral infection by administering a pharmaceutical composition of the invention to a site of infection or potential infection in a patient. The pharmaceutical composition is administered to the patient in accordance with the treatment being rendered. For example, the composition can be applied to a surgical incision or other opening as a liquid, topical cream or by any other suitable delivery means. For topical wounds, the pharmaceutical composition can be a topical cream, salve, dermal antiseptic, dressing (e.g., gauze, tape, etc.) or spray.
- Another aspect of the present invention is directed to a method of detecting P-type reactive bacteria in a body fluid sample. This method includes contacting a body fluid sample with a P-type receptor specific assay reagent in an amount to allow for the binding of any P-type reactive bacteria which may be present in the sample to the reagent. The reagent includes a solid-phase substrate coated with one or more proanthocyanidin compositions of the invention. A determination of whether P-type reactive bacteria are present in the sample can be assessed by the degree of agglutination in said sample. The presence of P-type reactive bacteria, especially P-typeE. coli, can be determined if agglutination occurs in the sample.
- Another embodiment of the invention provides a test for use in detecting P-type bacteria in a body fluid sample. The test includes use of a P-type receptor-specific assay reagent which includes a solid-phase substrate coated with one or more proanthocyanidin compositions of the invention. Multiple serial dilutions of the sample or reagent can be used to conduct the assay.
- The anti-adhesion activity of proanthocyanidin and proanthocyanidin polymers is believed to be potentiated or otherwise enhanced when combined with a substance selected from the group including Vaccinium-derived flavanols, especially galloyl-substituted tannins including gallocatechin, gallo-epicatechin, and pyranosides of these; Vaccinium-derived leukocyanins, and Vaccinium-derived flavonol pyranosides. Of these, a particularly preferred combination is the proanthocyanidin with the galloyl-substituted tannin, as the latter compounds are believed to inhibit enzymatic degradation of carbohydrate-substituted phenolic compounds. By themselves, the Vaccinium flavanols appear to have little or no anti-adhesion activity. However, at least some Vaccinium-derived flavonol pyranosides do have anti-adhesion activity, although less than the proanthocyanidins.
- Of the flavonol pyranosides present in the Vaccinium extract, myricetin-3-pyranoside is one of the most prominent. This compound does have some anti-adhesion activity, but it's anti-adhesion activity is less than that of the proanthocyanidin(s).
- At least three modes of bacterial cell adherence to other cells and surfaces are known. One mode is mediated by
type 1 pili on the surface of the bacteria and is characterized by sensitivity to free mannose. A second mode is mediated by P-type pili. The mechanisms of the third mode and other adherence modes are not well characterized. Guinea pig RBCs are believed to have receptors for the type 1 (mannose-sensitive) pili of E. coli, since the bacteria are capable of agglutinating guinea pig RBCs in the absence of mannose but not in its presence (see for example Aronsen, J. Infect. Dis. 139:329-332, 1979; Riegman, J. Bacter. 172: 1114-1120, 1990; Jann, Infect. Immun. 22:247-254, 1981). - The invention is further explained by use of the following illustrative EXAMPLES.
- The strain ofE. coli used for the tests on adherence to human bladder
TABLE I Comparison of HPLC Fractions in Guinea Pig RBC Agglutination Assay Fraction # Activity Index 510 6 512 4 514 5 516 2 518 1 520 0 522 0 524 0 526 4 504 18 506 18 508 6 500 0 502 5 - cells was isolated from an active bladder infection in a human subject. This strain, designated the #3B strain, appears to possess both
type 1 and P-type pili (the latter are sometimes referred to in the research literature as “P-type fimbriae”). - Results of the agglutination test for various substances and for the twoE. coli strains are shown in TABLE II. Gp indicates guinea pig cell assay; HU indicates human cell assay. In the guinea pig assay, the highest concentration of final extract in a 25 μl test dot was 0.056 mg/25 μl; the highest amount of anthocyanins in a dot was 0.063 mg/25 μl; the highest amount of mannose was 0.10 mg/25 μl.
TABLE II Comparison of Adhesion Inhibition by Extract to that by Known Substances Sample ID Blood Activity Index 1% mannose Gp 24 Final Extract Gp 10 EXPT. 1 Hu 13 Final Extract Gp 9 EXPT. 2 Hu 11 Alcohol Extract Gp 10 Anthocyanins Hu 0 Anthocyanins Gp 0 - Results of a similar test performed on a sample of the acidified alcohol extract, with the maximum amount being 0.4 mg/25 μl dot, are also shown. The anthocyanins used in the experiment shown in Table II were obtained from cranberries. The elution of the cation column with 1% HCl, after collection of the void volume and aqueous washes, is found to selectively recover much or all of the anthocyanin content of cranberry. The anthocyanin preparation did not contain significant amounts of other substances.
- From the results in Tables I and II, it is apparent that the cranberry extract inhibits both
type 1 pili-mediated adhesion of E. Coli to guinea pig RBCs and adhesion mediated by P-type pili. Since the extract contains virtually no free monomer or dimer sugars, the inhibition of P-type adhesion cannot be attributed to such sugars. Interestingly, P-type adhesion is believed to occur at high levels in E. coli in urinary tract infections. - The extract also reduced the adherence ofPseudomonas aeruginosa to bladder epithelial cells, although to a lesser degree than observed with E. coli. There was no apparent effect upon the adherence of several Lactobacillus strains to human bladder cells.
- Additionally,E. coli did not adhere to polystyrene plastic in the presence of the extract. However, it should be noted that, in general, E. coli do not tend to greatly adhere to polystyrene.
- A cranberry extract is used as a feed supplement for male mink. During the fall and early winter, male mink have a serious problem with bladder infections. This problem often occurs during the mating season and prevents the male mink from performing. A study was designed in which the mink were fed solid cranberry extract mixed in with their feed every morning. This study illustrated that the cranberry feed additive was helpful in reducing bladder infections in the male mink.
- The invention can also include compounds isolated from plant materials, particularly plants of the family Vitaceae, which have biological activity measurable as inhibition of adhesion of bacteria to surfaces, and an extract of such plant materials which is significantly enriched for anti-adhesion activity. Research has shown that members of the Vitaceae family, particularly of the Vitus genus, inhibit the adhesion of bacteria to surfaces and contain the active ingredients discussed throughout the present application. These extracts can be obtained by processes similar to the methods disclosed herein.
- FIGS.6B-6G depict analytical HPLC chromatograms of products from various steps in the process of FIG. 1. FIG. 6A is an HPLC chromatogram showing the retention time of two marker standards, catechin (peak 1400) and epicatechin (peak 1402), in the same HPLC protocol as FIGS. 6B-D. FIG. 6B is a chromatogram of the product of washing and air drying the precipitate which was analyzed for compounds absorbing at 280 nm and for compounds absorbing at 360 nm. FIG. 6C shows a chromatogram of the product of the eluate washed in the column with a ratio of 70:30 of acetone: water, also analyzed for compounds absorbing at 280 nm and at 360 nm. FIG. 6D shows a chromatogram of the product of the wash of the eluate of methanol: water at a 20:80 ratio, from which it is evident that essentially no 360 nm-absorbing compounds remain.
- The eluate of this step has been subjected to13C and 1H nuclear magnetic resonance analysis, mass spectrometry, and infrared absorbance analysis.
- FIG. 7 depicts a13C-NMR scan of product from the step of the 20:80 wash in d6-dimethylsulfoxide (“DMSO”).
Peak 1600 is from the DMSO and methanol solvents.Peak 1604 represents a C4 carbon of an epicatechin ring system, while peak 1606 represents a C4 carbon of a catechin ring system.Peaks 1608 represent the C3 and C4 carbons of a B-ring of a flavanol (catechin) ring system. - FIG. 8 depicts an1H-NMR scan of product from the aforementioned step, also in d6-DMSO.
- FIGS. 9A and 9B depict mass spectrograms of product from the aforementioned step, dissolved in 3- nitrobenzyl alcohol with DMSO.
- From this data, it is evident that the product from the aforementioned step has many of the characteristics of a proanthocyanidin. In addition, it is further believed that in addition to the dimer, the material in the
region 1410 beneath thepeak 1408 of the HPLC of FIG. 6C includes polymeric proanthocyanidins and that these polymeric proanthocyanidins are highly active as well polymeric proanthocyanidins. - Proanthocyanidin oligomers or polymers useful for present anti-microbial methods include monomeric units of leucoanthocyandins. Leucoanthocyandins are generally monomeric flavonoids which include catechins, epicatechins, gallocatechins, galloepicatechins, flavonols, and flavan-3,4-diols leucocyanidins and anthocyanidins. The proanthocyanidin polymers have 2 to 30 flavonoid units.
- In addition, it was found that crystal formation occurred upon storage of the LH-20 30% MeOH eluate under nitrogen for periods of from one to several weeks or more. Apparently, under slow purging of the nitrogen atmosphere, the eluate (generally 1-2 ml volume) becomes sufficiently concentrated that the purified active compound spontaneously crystallizes; such behavior is known for various polyphenolic compounds. Crystals grown from the 30% methanol eluate have been analyzed by X-ray crystallographic methods. From the data, it is evident that the product from the 20:80 mixture step has many characteristics of a proanthocyanidin. In addition, it is further believed that, in addition to the dimer, the material in the
region 1410 beneath thepeak 1408 of the HPLC of FIGS. 6D and 6E includes polymeric proanthocyanidins of various chain lengths up to 5000 Daltons molecular weight and that these are highly active as well. - Certain other compounds present in the extract have been farther identified as having anti-adhesion activity, and in some cases these compounds have been partially purified. These include leukocyanidins/leukodelphinidins and flavonol pyranosides. Leukocyanidins/leukodelphinidins and flavonol pyranosides include a general structure of a catechin molecule (Merck Index # 1908); epicatechin differs from catechin in the orientation of the hydroxyl at position 3, and the hydrogen at
position 2 of the phenol group. - In general, compounds having a ring system, wherein the ring B may include oxygen at
position 1,position 4, or both, and having a pyranoside as R2, have anti-adhesion activity. The ring B is further unsaturated except for the C═C bond shared with ring A. Evidence for the necessity of the unsaturation of ring B and the necessity of R2 being a pyranoside is as follows. Leucoanthocyanins (exemplified as leucocyanin and leucodelphinin) are colorless compounds having the catechin or epicatechin ring structure with an unsaturated ring B and a pyranoside in the R2 position. Upon treatment of leucocyanins by heating in aqueous acid solution, the O—R2 carbohydrate linkage is hydrolyzed and the result is a cyanidin (or delphinidin), wherein ring B is fully saturated and gives a characteristic red color. The material in certain HPLC peaks of the Vaccinium extract which absorb at 280 nm and are found to contain anti-adhesion activity is initially colorless. Upon treatment with heat and aqueous acid, carbohydrate moieties are released, red color appears in the fraction at the characteristic anthocyanin absorbance wavelength of 512 nm, and the activity in the material is lost. - Further, quercetin and myricetin, which both share the catechin or epicatechin-like nucleus with leucocyanins but have R2=H or OH, have been tested in the anti-adhesion assay and show no activity. However, myricetin-3-pyranoside isolated from Vaccinium species does have anti-adhesion activity. Further, as described previously herein, one of the anti-adhesion assays described herein compares the ability of a substance to inhibit binding relative to mannose inhibition of such adhesion, and it is, therefore, believed that a carbohydrate moiety is involved in conferring anti-adhesion activity.
- Based on the above observations, applicants conclude that wherein X=C or O; R1=H or OH; R2=H, OH, pyranoside, a pyranoside chain, or galloyl; R3=H or OH; R4=catechin, epicatechin, or procyanidin polymer; all possess some degree of inhibitory effect on adherence of microbes to cell surfaces. Further, the microbes whose adherence to cells is interfered with include bacteria, yeast and possibly viruses which bind to cell surfaces as a first step in infecting them.
- The invention is described with reference to specific embodiments, plant species and parts, buffers and chemical procedures and the like. However, it will be recognized by those skilled in the art that various substitutions can be made without departing from the spirit and scope of the invention. In particular, it is known that polyphenols including flavonoids and anthocyanins can be isolated and/or partially purified from plant materials by a number of different methods. It will further be recognized that these alternate methods, and consequent changes in other steps of the method including removal of sugars, of various solvents, and of anthocyanins from a composition including partially purified polyphenols, fall within the scope of the presently invented Vaccinium extract.
Claims (49)
1. A proanthocyanidin composition substantially purified for one or more proanthocyanidin compounds with a peak located at about 95 ppm on 13C NMR.
2. The proanthocyanidin composition of claim 1 comprising one or more proanthocyanidin compounds having an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units.
3. The proanthocyanidin composition of claim 2 , wherein said proanthocyanidin compounds consist of an average of four, five or six epicatechin flavanoid units.
4. A process for preparing a proanthocyanidin extract with a peak located at about 95 ppm on 13C NMR, said process comprising:
(a) homogenizing plant material in an aqueous extraction solvent comprising at least about 10% water but no more than about 30% water, about 10% to about 70% acetone, about 5% to about 60% methanol and about 0.05% to about 0.2% ascorbic acid to prepare a first extract;
(b) clarifying said first extract and obtaining a supernatant fraction therefrom;
(c) removing solvent from said supernatant fraction to obtain a residue and suspending said residue in distilled water to obtain an aqueous residue solution;
(d) subjecting said aqueous residue solution to further purification by either
(i) applying said aqueous residue solution to reverse-phase lipophilic chromatography material equilibrated in distilled water and successively washing said lipophilic chromatography material with a sufficient amount of distilled water to remove sugars, a sufficient amount of about 15% aqueous methanol to remove acids and a sufficient amount of 100% acidified methanol to elute polyphenolic compounds, and then removing solvent from said polyphenolic compounds to obtain a first dried fraction, or
(ii) extracting said aqueous residue solution with a non-polar extraction solvent, recovering the aqueous phase thereof and removing solvent from said aqueous phase to obtain a second dried fraction;
(e) suspending said first or second dried fraction in about 50% aqueous ethanol to obtain an ethanol solution, applying said ethanol solution to mixed hydrophilic-lipophilic chromatography material equilibrated in about 50% aqueous ethanol, and washing said mixed hydrophilic-lipophilic chromatography material with an amount of about 50% aqueous ethanol sufficient to remove non-proanthocyanidin polyphenolic compounds; and
(f) eluting said hydrophilic-lipophilic chromatography material with an amount of about 70% aqueous acetone sufficient to obtain said proanthocyanidin extract.
5. The process of claim 4 , wherein said plant material is from a plant in the family Ericaceae or Vitaceae.
6. The process of claim 4 , wherein said plant is a Vaccinium or Vitus species.
7. The process of claim 4 , wherein said Vaccinium plant material is from Vaccinium macrocarpon.
8. A pharmaceutical composition comprising the proanthocyanidin extract of claim 1 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising the proanthocyanidin composition produced by the process of claim 4 together with a pharmaceutically acceptable carrier.
10. A method of preventing or treating a urogenital infection in a mammal which method comprises administering a pharmaceutical composition according to claim 8 to said mammal in an amount and for a time sufficient to prevent, reduce or eliminate symptoms associated with said infection, wherein said pharmaceutical composition comprises a pharmaceutically-acceptable carrier in admixture with one or more
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli.
11. The method of claim 10 , wherein said mammal is a mink.
12. The method of claim 10 , wherein said mammal is a human.
13. The method of claim 10 , wherein said urogenital infection is a bladder infection or a kidney infection.
14. The method of claim 13 , wherein said kidney infection is pyelonephritis.
15. A food composition comprising a consumable carrier in admixture with a proanthocyanidin composition substantially purified for one or more proanthocyanidin compositions selected from one or more of the following:
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; and
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli.
16. The food composition of claim 15 wherein said consumable carrier is animal feed.
17. A method of preventing or treating a urogenital infection in a livestock animal which method comprises administering the food composition of claim 16 to said animal in an amount and for a time to prevent, reduce or eliminate symptoms associated with said infection.
18. A method of reducing the pathogenicity of P-type E. coli in the digestive tracts of an animal which method comprises:
administering the food composition of claim 16 to the animal for a time and in an amount to reduce the detectable number of P-type E. coli bacterial cells in the feces or urine of said animal.
19. The method of claim 18 , wherein said animal is a mammal.
20. A method of reducing P-type E. coli contamination in food which comprises:
(a) obtaining food; and
(b) adding the food composition of claim 15 to said food.
21. The method of claim 20 wherein said composition is added to said food before or during preparation of said food.
22. A method of reducing P-type E. coli contamination in food which comprises:
(a) obtaining an extract of a proanthocyanidin composition with a peak located at about 95 ppm on a 13C NMR.
(b) obtaining food; and
(c) adding to said food one or more of the following:
(i) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli;
(ii) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(iii) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(iv) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(v) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli.
23. The method of claim 22 wherein said composition is added to said food before or during preparation of said food.
24. A method of preventing or treating a urogenital infection in a domesticated animal which comprises administering the food composition of claim 16 to said animal in an amount and for a time to prevent, reduce or eliminate symptoms associated with said infection.
25. The method of claim 24 , wherein said animal is a mammal.
26. The food composition of claim 15 wherein said consumable carrier is a consumable food product.
27. The composition of claim 26 , wherein said consumable food product is a cranberry-containing food product.
28. The composition of claim 27 , wherein said cranberry-containing food product is a dried cranberry, a sweetened and dried cranberry, a flavored fruit piece, a sauce, a jelly, a relish, juice, wine or a cranberry juice-containing product.
29. The composition of claim 27 , wherein said consumable food product is a beverage.
30. The composition of claim 29 , wherein said beverage comprises cranberry juice, unpasteurized juice or pasteurized juice.
31. A method of preventing or treating a urogenital infection in a human which comprises administering a food composition of claim 26 to said human in an amount and for a time to prevent, reduce or eliminate symptoms associated with said infection.
32. A method of inhibiting adherence of P-type E. coli to a surface which comprises contacting said bacteria with at least one proanthocyanidin extract, compound or polymer, prior to or concurrently with contacting said bacteria with said surface, with the proanthocyanidin extract containing a peak located at about 95 ppm on a 13C NMR, wherein said proanthocyanidin extract, compound or polymer is selected from the group consisting of
(a) a substantially purified plant proanthocyanidin extract capable of inhibiting agglutination of P-type E. coli;
(b) a proanthocyanidin compound capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(c) a proanthocyanidin compound consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(d) a proanthocyanidin compound consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(e) a proanthocyanidin polymer capable of inhibiting agglutination of P-type E. coli.
33. The method of claim 32 , wherein said surface is a uroepithelial cell surface or biofilm.
34. A method of reducing the incidence of infection after surgery, treating topical wounds or acne, or preventing or eliminating oral infection which comprises administering a pharmaceutical composition to a site of infection or potential infection in a patient, wherein said pharmaceutical composition comprises a pharmaceutically-acceptable carrier in admixture with one or more
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR; or
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli.
35. A method of detecting P-type reactive bacteria in a body fluid sample which comprises:
(a) contacting said body fluid sample with a P-type receptor-specific assay reagent and for a time and in an amount to allow binding of any P-type reactive bacteria present in said sample to said reagent, wherein said reagent comprises a solid-phase substrate coated with one or more proanthocyanidin extracts, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR compounds or polymers selected from the group consisting of
(i) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(ii) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(iii) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(iv) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR; or
(v) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR; and
(b) determining whether P-type reactive bacteria are present in said sample by assessing the degree of agglutination is said sample, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR.
36. The method of claim 35 , wherein said plant extract is from a Vaccinium species.
37. The extract of claim 36 , wherein said Vaccinium species is Vaccinium macrocarpon.
38. A method of detecting P-type reactive bacteria in a body fluid sample which comprises:
(a) testing said body fluid sample with human red blood cells in a agglutination assay;
(b) testing said body fluid sample with guinea pig blood cells in a second agglutination assay; and
(c) determining the results thereof.
39. A method of preventing or treating a urinary tract infection in a mammal which method comprises administering a pharmaceutical composition to said mammal in an amount and for a time sufficient to prevent, reduce or eliminate symptoms associated with said infection, wherein said pharmaceutical composition comprises a pharmaceutically-acceptable carrier in admixture with one or more
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR; or
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR.
40. A method according to claim 39 wherein said proanthocyanidin extracts comprise of plant material from the family Vitaceae.
41. A method according to claim 40 wherein said Vitaceae plant material comprises of the Vitus species.
42. The proanthocyanidin composition of claim 1 comprising one or more proanthocyanidin compounds having an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units.
43. A method of preventing or treating a urogenital infection in a mammal which method comprises administering a pharmaceutical composition according to claim 8 to said mammal in an amount and for a time sufficient to prevent, reduce or eliminate symptoms associated with said infection, wherein said pharmaceutical composition comprises a pharmaceutically-acceptable carrier in admixture with one or more
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. Coli;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli but incapable of inhibiting agglutination of type 1 E. coli.
44. A food composition comprising a consumable carrier in admixture, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR, with one or more of the following:
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli but incapable of inhibiting agglutination of type 1 E. coli;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; and
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli but incapable of inhibiting agglutination of type 1 E. coli.
45. A method of reducing P-type E. coli contamination in food, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR, which comprises:
(a) obtaining food; and
(b) adding to said food one or more of the following:
(i) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli but incapable of inhibiting agglutination of type 1 E. coli;
(ii) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(iii) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(iv) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(v) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli but incapable of inhibiting agglutination of type 1 E. coli.
46. A method of inhibiting adherence of P-type E. coli to a surface which comprises contacting said bacteria with at least one proanthocyanidin extract, compound or polymer, prior to or concurrently with contacting said bacteria with said surface, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR, wherein said proanthocyanidin extract, compound or polymer is selected from the group consisting of
(a) a substantially purified plant proanthocyanidin extract capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli;
(b) a proanthocyanidin compound capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(c) a proanthocyanidin compound consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(d) a proanthocyanidin compound consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(e) a proanthocyanidin polymer capable of inhibiting agglutination of P-type E. coli but incapable of inhibiting agglutination of type 1 E. coli.
47. A method of reducing the incidence of infection after surgery, treating topical wounds or acne, or preventing or eliminating oral infection which comprises administering a pharmaceutical composition to a site of infection or potential infection in a patient, wherein said pharmaceutical composition comprises a pharmaceutically-acceptable carrier in admixture with one or more
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR; or
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR.
48. A method of detecting P-type reactive bacteria in a body fluid sample which comprises:
(a) contacting said body fluid sample with a P-type receptor-specific assay reagent and for a time and in an amount to allow binding of any P-type reactive bacteria present in said sample to said reagent, wherein said reagent comprises a solid-phase substrate coated with one or more proanthocyanidin extracts, compounds or polymers, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR, selected from the group consisting of
(i) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli;
(ii) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(iii) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(iv) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(v) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli; and
(b) determining whether P-type reactive bacteria are present in said sample by assessing the degree of agglutination is said sample, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR.
49. A method of preventing or treating a urinary tract infection in a mammal, wherein the proanthocyanidin extract contains a peak located at about 95 ppm on a 13C NMR, which method comprises administering a pharmaceutical composition to said mammal in an amount and for a time sufficient to prevent, reduce or eliminate symptoms associated with said infection, wherein said pharmaceutical composition comprises a pharmaceutically-acceptable carrier in admixture with one or more
(a) substantially purified plant proanthocyanidin extracts capable of inhibiting agglutination of P-type E. coli, but incapable of inhibiting agglutination of type 1 E. coli;
(b) proanthocyanidin compounds capable of inhibiting agglutination of P-type E. coli, wherein said polymer comprises two or more flavanoid monomer units wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of any units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(c) proanthocyanidin compounds consisting of an average of from at least four to about seven epicatechin flavanoid units, wherein at least two of said units are linked together by an A-type interflavanoid linkage by bonds between C4 and C8 and between the C2 and the oxygen of C7 of the units and the remainder of the units are linked to each other by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units;
(d) proanthocyanidin compounds consisting of an average of from at least four to about twelve epicatechin flavanoid units, wherein each unit is linked to the next by a B-type interflavanoid bond between C4 and C8 or between C4 and C6 of the units; or
(e) proanthocyanidin polymers capable of inhibiting agglutination of P-type E. coli but incapable of inhibiting agglutination of type 1 E. coli.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/920,511 US20020028260A1 (en) | 1999-09-07 | 2001-08-01 | Plant proanthocyanidin extracts |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/391,308 US6210681B1 (en) | 1999-09-07 | 1999-09-07 | Plant proanthocyanidin extracts |
US09/822,710 US6440471B2 (en) | 1999-09-07 | 2001-03-30 | Plant proanthocyanidin extracts |
US09/920,511 US20020028260A1 (en) | 1999-09-07 | 2001-08-01 | Plant proanthocyanidin extracts |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/822,710 Division US6440471B2 (en) | 1999-09-07 | 2001-03-30 | Plant proanthocyanidin extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020028260A1 true US20020028260A1 (en) | 2002-03-07 |
Family
ID=23546104
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/391,308 Expired - Fee Related US6210681B1 (en) | 1999-09-07 | 1999-09-07 | Plant proanthocyanidin extracts |
US09/822,710 Expired - Fee Related US6440471B2 (en) | 1999-09-07 | 2001-03-30 | Plant proanthocyanidin extracts |
US09/920,511 Abandoned US20020028260A1 (en) | 1999-09-07 | 2001-08-01 | Plant proanthocyanidin extracts |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/391,308 Expired - Fee Related US6210681B1 (en) | 1999-09-07 | 1999-09-07 | Plant proanthocyanidin extracts |
US09/822,710 Expired - Fee Related US6440471B2 (en) | 1999-09-07 | 2001-03-30 | Plant proanthocyanidin extracts |
Country Status (1)
Country | Link |
---|---|
US (3) | US6210681B1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060067961A1 (en) * | 2004-09-30 | 2006-03-30 | Kimberly-Clark Worldwide,Inc. | Skin cooling compositions |
EP1661576A1 (en) * | 2004-11-15 | 2006-05-31 | Pharmatoka SAS | New dermatological and/or cosmetic use of a plant extract |
US20080064050A1 (en) * | 2006-09-07 | 2008-03-13 | The Government Of The Us, As Represented By The Secretary Of The Navy | Applications of the binding interaction of proanthocyanidins with bacteria and bacterial components |
EP1913951A1 (en) * | 2006-10-17 | 2008-04-23 | Pharmatoka SAS | Method for the extraction of polyphenols and uses thereof |
US20090035226A1 (en) * | 2007-07-31 | 2009-02-05 | Phenolics, Llc | Use of cranberry extract enriched in total phenols and free, essentially free, or substantially free of sugars, acids, sulfur and other contaminants, for periodontal treatment |
US20090118202A1 (en) * | 2007-10-31 | 2009-05-07 | Texas Tech University | Compositions and methods of treating hypertension with tannin complexes |
WO2009089442A1 (en) * | 2008-01-11 | 2009-07-16 | U.S. Nutraceuticals, Llc D/B/A/ Valensa International | Use of cranberry derivative and d-mannose composition for preventing, controlling and ameliorating urinary tract infections |
US20090226548A1 (en) * | 2008-01-11 | 2009-09-10 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition |
EP2108268A1 (en) * | 2008-04-09 | 2009-10-14 | Diana Naturals | Extract of American cranberry and use thereof. |
US20090258940A1 (en) * | 2008-04-09 | 2009-10-15 | Matthieu Besnard | American cranberry extract and its use |
US20100019197A1 (en) * | 2004-04-27 | 2010-01-28 | Tadahiro Hiramoto | Deoxidant composition |
US20100184850A1 (en) * | 2007-06-12 | 2010-07-22 | Consejo Superior De Investigaciones Cientificas | Phenolic extracts of almond peel containing procyanidins, propelargonidins, and prodelphinidins, and method for preparation thereof |
US20110064706A1 (en) * | 2008-01-11 | 2011-03-17 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend |
US20130316025A1 (en) * | 2012-05-25 | 2013-11-28 | Ocean Spray Cranberries, Inc. | Cranberry Xyloglucan Oligosaccharide Composition |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1014969B1 (en) | 1997-09-09 | 2008-11-12 | Rutgers, The State University of New Jersey | Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces |
US6544581B1 (en) * | 1999-06-22 | 2003-04-08 | Canandaigua Wine Company, Inc. | Process for extraction, purification and enrichment of polyphenolic substances from whole grapes, grape seeds and grape pomace |
WO2002017945A1 (en) * | 2000-08-31 | 2002-03-07 | Hauser, Inc. | Efficient method for producing compositions enriched in anthocyanins |
US6960360B2 (en) * | 2000-08-31 | 2005-11-01 | Phenolics, Llc | Efficient method for producing compositions enriched in total phenols |
US7306815B2 (en) * | 2000-08-31 | 2007-12-11 | Phenolics, Llc | Compositions enriched in phenolic compounds and methods for producing the same |
US7022368B2 (en) * | 2001-06-26 | 2006-04-04 | Ocean Spray Cranberries, Inc. | Process for producing sugars and acids-rich juice and phytochemical-rich juice |
US7001625B2 (en) * | 2001-07-30 | 2006-02-21 | Kemin Industires, Inc. | Solid phase synthesis of salts of organic acids including butyric acid |
US6733813B2 (en) | 2001-08-02 | 2004-05-11 | Ocean Spray Cranberries, Inc. | Process for producing acids-enriched juice and acids-reduced juice |
GB0230042D0 (en) * | 2002-12-23 | 2003-01-29 | Britannia Pharmaceuticals Ltd | Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
US20040151716A1 (en) * | 2003-02-03 | 2004-08-05 | Hamer Richard A. | Material and method for treating microbial mediated dermatological conditions |
US7270837B2 (en) * | 2003-11-10 | 2007-09-18 | Rutgers, The State University Of New Jersey | Anti-inflammatory cranberry flavonol extract preparations |
US20050129790A1 (en) * | 2003-11-17 | 2005-06-16 | Folts John D. | Polyphenol-containing stem and vine extracts and methods of use |
US7332179B2 (en) * | 2003-12-12 | 2008-02-19 | Kimberly-Clark Worldwide, Inc. | Tissue products comprising a cleansing composition |
GB0405540D0 (en) * | 2004-03-11 | 2004-04-21 | Glaxo Group Ltd | Novel use |
US20050244480A1 (en) * | 2004-04-30 | 2005-11-03 | Kimberly-Clark Worldwide, Inc. | Pre-wipes for improving anal cleansing |
US20060073220A1 (en) * | 2004-07-08 | 2006-04-06 | Daugherty F J | Cinnamon extract enriched for polyphenols and methods of preparing same |
US7642395B2 (en) * | 2004-12-28 | 2010-01-05 | Kimberly-Clark Worldwide, Inc. | Composition and wipe for reducing viscosity of viscoelastic bodily fluids |
US20060140899A1 (en) * | 2004-12-28 | 2006-06-29 | Kimberly-Clark Worldwide, Inc. | Skin cleansing system comprising an anti-adherent formulation and a cationic compound |
AU2006242106B2 (en) * | 2005-05-02 | 2013-01-17 | 4Life Patents, Llc | Transfer factor preparations and associated methods |
US9028882B2 (en) | 2005-05-02 | 2015-05-12 | 4Life Patents, Llc | Nutraceutical gels |
ES2379197T3 (en) * | 2007-08-01 | 2012-04-23 | Ferlux S.A. | Preparation procedure for extracts rich in proanthocyanidins |
DE202008002718U1 (en) * | 2008-02-26 | 2009-07-09 | Medical Service Gmbh | Catheter with proanthocyanidin-containing hydrophilic coating |
ES2612343T3 (en) | 2009-04-16 | 2017-05-16 | Ocean Spray Cranberries, Inc. | Extraction of phenolic compounds and their use in compositions with fumaric acid |
CN102781928B (en) * | 2010-01-15 | 2016-05-18 | 优鲜沛蔓越莓公司 | For extract method and the Related product of compound from european cranberry leaf |
US20140004214A1 (en) * | 2012-06-15 | 2014-01-02 | Wisconsin Alumni Research Foundation | Methods to isolate anti-microbials from fruit or seed extracts |
CN104496957A (en) * | 2014-12-01 | 2015-04-08 | 成都红柿子科技有限公司 | Method for extracting procyanidine from grape skins |
CN106938028A (en) * | 2017-04-13 | 2017-07-11 | 龙文杰 | A kind of health liquor of warming and invigorating kidney Yang and preparation method thereof |
MX2020009313A (en) * | 2018-03-08 | 2020-11-24 | Plexus Worldwide Llc | Compositions and methods for skin renewal. |
BR112021004284A2 (en) | 2018-09-07 | 2021-05-25 | Innophos, Inc. | botanical antioxidants |
EP3846834A1 (en) | 2018-09-07 | 2021-07-14 | Innophos, Inc. | Anti-inflammatory botanical extract |
CA3110996A1 (en) * | 2018-09-07 | 2020-03-12 | Innophos, Inc. | Botanical modulator of metabolic disorders |
CN113208017A (en) * | 2021-05-19 | 2021-08-06 | 北京果耶有限公司 | Plum syrup and preparation method thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963700A (en) | 1974-07-01 | 1976-06-15 | University Patents, Inc. | Recovery of anthocyanin from plant sources |
FR2318908A1 (en) | 1975-07-22 | 1977-02-18 | Sefcal Sarl | PROCESS FOR TREATMENT OF ANTHOCYANIC EXTRACTS |
FR2461499A1 (en) | 1979-07-23 | 1981-02-06 | Inverni Della Beffa Spa | Topical compsns. with cicatrising activity - contg. bilberry vaccinium myrtillus extract with high anthocyanoside content |
US4309207A (en) | 1980-01-07 | 1982-01-05 | Devlin Robert M | Plant growth inhibiting and antifungal extract prepared from the vegetative parts of plants of the genera vaccinium and myrica |
US4652448A (en) | 1982-10-07 | 1987-03-24 | Molecular Genetics, Inc. | Use of monoclonal antibodies against bacterial adhesins |
SE446940B (en) | 1983-02-16 | 1986-10-20 | Carl Axel Virdalm | MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITS |
DE3427014A1 (en) | 1984-07-21 | 1986-01-23 | Moser, Hanspeter H., Dr.med., 3012 Langenhagen | Product for the prophylaxis and therapy of uncomplicated urinary tract infections |
US4775477A (en) | 1987-10-30 | 1988-10-04 | General Foods Corporation | Cranberry color extraction |
ES2078339T3 (en) | 1989-05-12 | 1995-12-16 | Cariel Leon | COMPOSITIONS BASED ON PROANTOCIANIDOLES; YOUR PHARMACOLOGICAL APPLICATION. |
IT1231725B (en) | 1989-08-11 | 1991-12-21 | Inverni Della Beffa Spa | PROCEDURE FOR THE PREPARATION OF HIGH-CONTENT EXTRACTS IN ANTOCYANOSIDES. |
US5128100A (en) | 1989-10-12 | 1992-07-07 | Buckman Laboratories, Intl., Inc. | Process for inhibiting bacterial adhesion and controlling biological fouling in aqueous systems |
CN1054899A (en) | 1990-09-14 | 1991-10-02 | 贵阳生物化学制药厂 | Miganling instant herbal medicine, syrup production technology |
US5211944A (en) | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
US5650432A (en) | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
US5525341A (en) * | 1992-10-09 | 1996-06-11 | Jlb, Inc. | Partially purified cranberry anti-adhesion activity |
US5646178A (en) | 1992-10-09 | 1997-07-08 | Jlb, Inc. | Cranberry extract and biologically active compounds derived therefrom |
US5474774A (en) | 1994-03-25 | 1995-12-12 | Jlb, Inc. | Adhesion inhibiting composition |
EP1014969B1 (en) * | 1997-09-09 | 2008-11-12 | Rutgers, The State University of New Jersey | Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces |
-
1999
- 1999-09-07 US US09/391,308 patent/US6210681B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 US US09/822,710 patent/US6440471B2/en not_active Expired - Fee Related
- 2001-08-01 US US09/920,511 patent/US20020028260A1/en not_active Abandoned
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100019197A1 (en) * | 2004-04-27 | 2010-01-28 | Tadahiro Hiramoto | Deoxidant composition |
US20060067961A1 (en) * | 2004-09-30 | 2006-03-30 | Kimberly-Clark Worldwide,Inc. | Skin cooling compositions |
EP1661576A1 (en) * | 2004-11-15 | 2006-05-31 | Pharmatoka SAS | New dermatological and/or cosmetic use of a plant extract |
US20080064050A1 (en) * | 2006-09-07 | 2008-03-13 | The Government Of The Us, As Represented By The Secretary Of The Navy | Applications of the binding interaction of proanthocyanidins with bacteria and bacterial components |
US20080176933A1 (en) * | 2006-09-07 | 2008-07-24 | The Government Of The Us, As Represented By The Secretary Of The Navy | Binding interaction of proanthocyanidins with bacteria and bacterial components |
US9040250B2 (en) | 2006-09-07 | 2015-05-26 | The United States Of America, As Represented By The Secretary Of The Navy | Binding interaction of proanthocyanidins with bacteria and bacterial components |
US8715949B2 (en) | 2006-09-07 | 2014-05-06 | The United States Of America, As Represented By The Secretary Of The Navy | Applications of the binding interaction of proanthocyanidins with bacteria and bacterial components |
EP1913951A1 (en) * | 2006-10-17 | 2008-04-23 | Pharmatoka SAS | Method for the extraction of polyphenols and uses thereof |
US8802165B2 (en) | 2007-06-12 | 2014-08-12 | Consejo Superior De Investigaciones Cientificas | Phenolic extracts of almond peel containing procyanidins, propelargonidins, and prodelphinidins, and method for preparation thereof |
US20100184850A1 (en) * | 2007-06-12 | 2010-07-22 | Consejo Superior De Investigaciones Cientificas | Phenolic extracts of almond peel containing procyanidins, propelargonidins, and prodelphinidins, and method for preparation thereof |
US20090035226A1 (en) * | 2007-07-31 | 2009-02-05 | Phenolics, Llc | Use of cranberry extract enriched in total phenols and free, essentially free, or substantially free of sugars, acids, sulfur and other contaminants, for periodontal treatment |
WO2009018470A1 (en) * | 2007-07-31 | 2009-02-05 | Phenolics, Llc | Use of cranberry extract enriched in total phenols and free essentially free, or substantially free of sugars, acids, sulfur and other contaminants, for periodontal treatment |
US20090118202A1 (en) * | 2007-10-31 | 2009-05-07 | Texas Tech University | Compositions and methods of treating hypertension with tannin complexes |
US20090226548A1 (en) * | 2008-01-11 | 2009-09-10 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition |
US20090180999A1 (en) * | 2008-01-11 | 2009-07-16 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition |
US20110064706A1 (en) * | 2008-01-11 | 2011-03-17 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend |
KR101369538B1 (en) | 2008-01-11 | 2014-03-04 | 유.에스. 뉴트라수티칼스, 엘.엘.씨. | Use of cranberry derivative and d-mannose composition for preventing, controlling and ameliorating urinary tract infections |
WO2009089442A1 (en) * | 2008-01-11 | 2009-07-16 | U.S. Nutraceuticals, Llc D/B/A/ Valensa International | Use of cranberry derivative and d-mannose composition for preventing, controlling and ameliorating urinary tract infections |
EP2108268A1 (en) * | 2008-04-09 | 2009-10-14 | Diana Naturals | Extract of American cranberry and use thereof. |
US20090258940A1 (en) * | 2008-04-09 | 2009-10-15 | Matthieu Besnard | American cranberry extract and its use |
FR2929853A1 (en) * | 2008-04-09 | 2009-10-16 | Diana Naturals Soc Par Actions | CANCER EXTRACT FROM AMERICA AND USE THEREOF |
US20130316025A1 (en) * | 2012-05-25 | 2013-11-28 | Ocean Spray Cranberries, Inc. | Cranberry Xyloglucan Oligosaccharide Composition |
US9314494B2 (en) * | 2012-05-25 | 2016-04-19 | The United States Of America, As Represented By The Secretary Of Agriculture | Cranberry xyloglucan oligosaccharide composition |
Also Published As
Publication number | Publication date |
---|---|
US20010021398A1 (en) | 2001-09-13 |
US6440471B2 (en) | 2002-08-27 |
US6210681B1 (en) | 2001-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6210681B1 (en) | Plant proanthocyanidin extracts | |
KR100343486B1 (en) | Plant extract having antibacterial adhesion inhibition activity, its preparation method and composition containing the same | |
AU744527B2 (en) | Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with P-type fimbriae to surfaces | |
US5646178A (en) | Cranberry extract and biologically active compounds derived therefrom | |
US8575368B2 (en) | Proanthocyanidin of cashew apple, composition containing proanthocyanidin, and application thereof | |
US5650432A (en) | Method of treating or preventing non-viral microbial infection | |
AU2003295856B2 (en) | Efficient method for producing compositions enriched in total phenols | |
AU2005209252A1 (en) | Compositions enriched in phenolic compounds and methods for producing the same | |
WO2006068212A1 (en) | Lipase inhibitor and preventive/remedy for skin diseases | |
US20040013710A1 (en) | Hydrolyzable tannin extracts from plants effective at inhibiting bacterial adherence to surfaces | |
WO2002007746A1 (en) | Hydrolyzable tannin extracts from plants effective at inhibiting bacterial adherence to surfaces | |
JPH10218786A (en) | Medicine comprising buckwheat chaff extract as active ingredient | |
Chitte et al. | Detection of phytoconstituents of medicinal plant Terminalia arjuna using chromatographic techniques | |
JP5591122B2 (en) | Cashew apple proanthocyanidins, proanthocyanidin-containing compositions, and uses thereof | |
AU773196B2 (en) | Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with P-type fimbriae to surfaces | |
Coolborn et al. | Antimicrobial activities, phytochemical and antioxidant analyses of Phyllanthus mullerianus (KUNTZ) Exell methanol and aqueous leaf extracts | |
Roja | Growth and Characterization of Calcium Hydrogen Phosphate Dihydrate Urinary Stone and Inhibitory Effect of Juice And Seed of Vitus vinifera | |
RU2000106034A (en) | VEGETABLE PROANTHOCYANIDINE EXTRACT EFFECTIVE AT INHIBITING ADHESION TO SURFACES OF BACTERIA WITH R-TYPE FIBRIA | |
Neto et al. | Food & Function | |
MXPA96004307A (en) | Composite for adhes inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RUTGERS, THE STATE UNIVERSITY, (RUTGERS), NEW JERS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JLB, INC.;REEL/FRAME:013570/0922 Effective date: 20021024 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |